What are the indications, starting dose, titration, contraindications, and monitoring recommendations for initiating ivabradine in patients with chronic stable angina or heart failure with reduced ejection fraction who are already on maximally tolerated beta‑blocker therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 8, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ivabradine for Heart Failure and Chronic Coronary Syndrome

Ivabradine is indicated for adult patients with stable, symptomatic chronic heart failure with LVEF ≤35%, who are in sinus rhythm with resting heart rate ≥70 bpm, and are on maximally tolerated beta-blockers or have contraindications to beta-blockers. 1

Indications

Heart Failure with Reduced Ejection Fraction (Primary Indication)

  • LVEF ≤35%
  • Symptomatic (NYHA class II-III) stable chronic heart failure
  • Sinus rhythm with resting heart rate ≥70 bpm
  • On maximally tolerated beta-blocker OR contraindication to beta-blockers
  • Reduces risk of hospitalization for worsening heart failure and cardiovascular death 2, 1

Chronic Coronary Syndrome (NOT Recommended)

Ivabradine is NOT recommended as add-on therapy in patients with chronic coronary syndrome, LVEF >40%, and no clinical heart failure. 3 The SIGNIFY trial demonstrated no benefit and potential harm in stable CAD patients without heart failure, particularly those with activity-limiting angina 4.

Dosing and Titration

Starting Dose

  • Standard patients: 5 mg twice daily with food 1
  • Vulnerable patients (conduction defects, risk of hemodynamic compromise): 2.5 mg twice daily 1

Titration Protocol (Assess after 2 weeks)

Resting Heart Rate Action
>60 bpm Increase by 2.5 mg twice daily (maximum 7.5 mg twice daily)
50-60 bpm Maintain current dose
<50 bpm or symptomatic bradycardia Decrease by 2.5 mg twice daily; if on 2.5 mg twice daily, discontinue

1

Target heart rate: 50-60 bpm 1

Critical Contraindications

Absolute Contraindications 1

  • Acute decompensated heart failure
  • Clinically significant hypotension
  • Sick sinus syndrome, sinoatrial block, or 3rd-degree AV block (unless functioning pacemaker present)
  • Clinically significant bradycardia
  • Severe hepatic impairment
  • Pacemaker dependence (heart rate maintained exclusively by pacemaker)
  • Concomitant use of strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, nefazodone, ritonavir, nelfinavir)

Important Caveat

Do NOT combine ivabradine with non-dihydropyridine calcium channel blockers (diltiazem, verapamil) or other strong CYP3A4 inhibitors. 3, 1

Monitoring Requirements

Before Initiation

  • Confirm sinus rhythm (ECG)
  • Document resting heart rate ≥70 bpm
  • Verify LVEF ≤35%
  • Ensure beta-blocker optimized to maximally tolerated dose
  • Check for conduction abnormalities

During Treatment

  • Heart rate monitoring: Check at 2 weeks, then regularly during dose adjustments 1
  • Cardiac rhythm monitoring: Regularly monitor for atrial fibrillation development 1
    • Atrial fibrillation occurred in 5.0% per patient-year with ivabradine vs 3.9% with placebo 1
    • Discontinue ivabradine if atrial fibrillation develops 1
  • Bradycardia assessment: Monitor for symptoms (dizziness, fatigue, syncope)
    • Bradycardia rate: 6.0% per patient-year (2.7% symptomatic) 1

Special Monitoring Situations

  • Patients with 1st or 2nd-degree AV block: Not recommended, but if used, close monitoring required 1
  • Concomitant negative chronotropes (digoxin, amiodarone): Increased bradycardia risk, monitor heart rate closely 1

Key Clinical Pitfalls

Beta-Blocker Optimization First

Critical point: Only 25% of patients in the SHIFT trial were on optimal beta-blocker doses 2. Given beta-blockers' proven mortality benefit, uptitrate beta-blockers to target doses before considering ivabradine 2. Ivabradine is an adjunct, not a replacement.

Wrong Population

Do not use ivabradine in:

  • Chronic coronary syndrome without heart failure (LVEF >40%) 3
  • Heart failure with preserved ejection fraction 5
  • Acute heart failure 1

Drug Interactions

Avoid CYP3A4 inhibitors and inducers entirely. Even moderate inhibitors (grapefruit juice) can significantly increase ivabradine levels 1.

Pregnancy and Contraception

Ivabradine causes fetal toxicity. Advise females of reproductive potential to use effective contraception during treatment 1. Breastfeeding is not recommended 1.

Evidence Quality Note

The primary evidence supporting ivabradine comes from the SHIFT trial 2, which demonstrated reduction in heart failure hospitalization (the greatest benefit) and cardiovascular death in HFrEF patients. However, the benefit was most pronounced in patients with heart rates >70 bpm and on suboptimal beta-blocker doses, emphasizing the importance of beta-blocker optimization first 2, 6.

References

5
Research

Clinical Implications of Ivabradine in the Contemporary Era.

Medicina (Kaunas, Lithuania), 2024

Related Questions

What is the role of ivabradine in chronotropic (heart rate) control?
What is the recommended usage and dosage of Ivabradine (Ivabradine) for an adult patient with a history of cardiovascular disease, symptomatic heart failure with reduced ejection fraction, and symptoms such as shortness of breath or fatigue?
What is the use of Ivabradine (Corlanor)?
What medication should be added to a patient with heart failure with reduced ejection fraction (EF) and dilated cardiomyopathy, already on Valsartan (angiotensin II receptor antagonist), statin (HMG-CoA reductase inhibitor), metoprolol (beta-blocker), spironolactone (aldosterone antagonist), and furosemide (loop diuretic)?
When is Ivabradine (Ivabradine) indicated for use in patients with heart failure with reduced ejection fraction (HFrEF) and what is the typical dosing regimen?
What self‑care recommendations are appropriate for patients with acute pharyngitis?
For a patient with type 2 diabetes scheduled for liver transplantation tomorrow and who will be NPO after midnight, with a current basal insulin glargine (Lantus) dose of 18 units daily, what should the Lantus dose be tomorrow?
What are the indications, dosing regimens, and monitoring parameters for sodium bicarbonate use in adult patients?
What are the appropriate dosing regimens for labetalol, nicardipine, and sodium nitroprusside in an adult presenting with a hypertensive emergency?
What are the recommended anticalcemic measures for managing hypercalcemia?
What is hyperammonemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question